Company intelligence / Profile preview
Perseo Pharma
Muttenz, Basel-Landschaft, Switzerland
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Perseo Pharma has established preclinical proof-of-concept for multiple oral enzyme replacement therapies. Lead candidate (PER301) for digestive enzyme deficiency is anticipated to enter first-in-human in 2025. Platform applications for rare metabolic and lysosomal storage disorders are in early research stages.
- Therapeutic areas
- Metabolic DisordersRare DiseasesGastroenterology
- Modalities
- Enzyme replacement therapyRecombinant proteinNanoparticleBiologic
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Nestlé Health ScienceUndisclosed biotech company (for IBD)
Beyond the preview
Go deeper on Perseo Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Perseo Pharma.